Literature DB >> 16189175

The negative association between total ghrelin levels, body mass and insulin secretion is lost in hypercortisolemic patients with Cushing's disease.

Roberta Giordano1, Andrea Picu, Uberto Pagotto, Rosaria De Iasio, Lorenza Bonelli, Flavia Prodam, Fabio Broglio, Lisa Marafetti, Renato Pasquali, Mauro Maccario, Ezio Ghigo, Emanuela Arvat.   

Abstract

OBJECTIVE: Ghrelin exerts a wide spectrum of endocrine and non-endocrine actions. The stomach is the major source of circulating ghrelin levels that are negatively associated with body mass, insulin and glucose levels. The role of glucocorticoids in ghrelin secretion and action is still unclear.
DESIGN: In 8 patients with Cushing's disease (CD, BMI 29.8 +/- 1.6 kg/m(2)), 7 normal (NS) and 6 obese subjects (OB, BMI 32.9 +/- 1.1 kg/m(2)) we studied: a) total ghrelin levels (every 15 min over 3 h) and their correlation with BMI, insulin, glucose, homeostatic model assessment (HOMA) index, ACTH and cortisol levels; b) GH, ACTH, cortisol, insulin and glucose responses to acylated ghrelin administration (1.0 mug/kg i.v. at 0 min).
RESULTS: CD patients had BMI, insulin and glucose levels as well as HOMA index higher than those in NS (P < 0.05) but similar to those in OB. Despite this, total ghrelin levels in CD were similar to those in NS and both were higher (P < 0.05) than those in OB. No correlation was found among total ghrelin and BMI, insulin, glucose, ACTH and cortisol levels in CD patients. The GH responses to ghrelin in CD and OB were similar and both were lower (P < 0.002) than those in NS. In CD ghrelin induced exaggerated ACTH and cortisol responses clearly higher (P < 0.005) than in OB and NS. Ghrelin administration increased glucose in all groups; insulin levels showed slight decrease that was significant (P < 0.05) in OB only.
CONCLUSIONS: Hypercortisolism in humans is associated with impaired ghrelin secretion and action. In fact, total ghrelin secretion in CD is not reduced despite increased BMI, insulin and glucose levels, while the GH and ACTH responses to acylated ghrelin are clearly reduced and enhanced, respectively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16189175     DOI: 10.1530/eje.1.02003

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.

Authors:  Silvia Regina Correa-Silva; Sérgio Oliva Nascif; Ana-Maria Judith Lengyel
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 2.  Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications.

Authors:  G Arnaldi; T Mancini; G Tirabassi; L Trementino; M Boscaro
Journal:  J Endocrinol Invest       Date:  2012-04       Impact factor: 4.256

3.  Acute ghrelin response to intravenous dexamethasone administration in idiopathic short stature or isolated idiopathic growth hormone-deficient children.

Authors:  G Radetti; F Prodam; S Lauriola; G Di Dio; G D'Addato; G Corneli; S Bellone; G Bona
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

Review 4.  Ghrelin in neuroendocrine organs and tumours.

Authors:  Chrysanthia A Leontiou; Giulia Franchi; Márta Korbonits
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

5.  Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.

Authors:  Sergio Oliva Nascif; Silvia Regina Correa-Silva; Marcos Roberto Silva; Ana-Maria Judith Lengyel
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

Review 6.  Ghrelin.

Authors:  T D Müller; R Nogueiras; M L Andermann; Z B Andrews; S D Anker; J Argente; R L Batterham; S C Benoit; C Y Bowers; F Broglio; F F Casanueva; D D'Alessio; I Depoortere; A Geliebter; E Ghigo; P A Cole; M Cowley; D E Cummings; A Dagher; S Diano; S L Dickson; C Diéguez; R Granata; H J Grill; K Grove; K M Habegger; K Heppner; M L Heiman; L Holsen; B Holst; A Inui; J O Jansson; H Kirchner; M Korbonits; B Laferrère; C W LeRoux; M Lopez; S Morin; M Nakazato; R Nass; D Perez-Tilve; P T Pfluger; T W Schwartz; R J Seeley; M Sleeman; Y Sun; L Sussel; J Tong; M O Thorner; A J van der Lely; L H T van der Ploeg; J M Zigman; M Kojima; K Kangawa; R G Smith; T Horvath; M H Tschöp
Journal:  Mol Metab       Date:  2015-03-21       Impact factor: 7.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.